Medicine and Health Sciences Commons^™

Calcium Phosphate Nanoparticles: A Future Therapeutic Platform For The Treatment Of Osteomyelitis?, Tejal A. Dasai, Vuk Uskoković

Pharmacy Faculty Articles and Research

No abstract provided.

Principles Of Management Of Severe Hyponatremia, Antonios H. Tzamaloukas Md, Deepak Malhorta Md, Phd, Bradley H. Rosen Do, Dominic S. C. Raj S. C. Raj Md, Glen H. Murata Md, Joseph I. Shapiro Md

Pharmaceutical Science and Research

Hyponatremia represents a serious health hazard.¹ Hospitalized patients,² nursing home residents,³ women,^4,5 and children⁶ exhibit high frequency and/or severity of hyponatremia. Hyponatremia developing during the course of other morbid conditions increases their severity.^7–10 Estimates of direct costs for treating hyponatremia in the United States ranged between $1.61 and $3.6 billion.¹¹

Clinical manifestations of hyponatremia are universal^12,13 and range from subtle (disturbances of balance, problems in cognition detected only during specific testing) to life-threatening manifestations of increased intracranial pressure with life-threatening hypoxia^14–16 and noncardiac pulmonary edema.¹⁷ Although the treating physicians must …

An Update On Braf Inhibitors And Other New Molecular Targets For The Treatment Of Malignant Melanoma Of The Skin, M. O. Faruk Khan, Carroll L. Ramos

Pharmaceutical Science and Research

Malignant melanoma of the skin originates from mutations in melanocytes and can be lethal if unrecognized or untreated in its earlier stages. Deaths from melanoma are increasing in the United States and around the world every year. The available treatments produce low rates of response with modest survival impact. Among potential molecular targets under investigation, which are mostly in the tyrosine kinase pathway, the BRAF (V-raf murine sarcoma viral oncogene homolog B1) gene is the best studied and most frequently reported mutation in melanoma. The molecular targets for melanoma treatment, promising drugs for future melanoma treatment as well as the …